BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31686136)

  • 21. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
    Allard MA; Sebagh M; Ruiz A; Guettier C; Paule B; Vibert E; Cunha AS; Cherqui D; Samuel D; Bismuth H; Castaing D; Adam R
    J Hepatol; 2015 Jul; 63(1):83-92. PubMed ID: 25646884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis.
    Hsieh PM; Hsiao P; Chen YS; Yeh JH; Hung CM; Lin HY; Ma CH; Tang T; Huang YW; Cheng PN; Hsieh KC; Hu KC; Bair MJ; Lin CW
    Kaohsiung J Med Sci; 2023 Mar; 39(3):302-310. PubMed ID: 36625289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
    Zheng L; Li HL; Guo CY; Luo SX
    Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim NH; Lee T; Cho YK; Kim BI; Kim HJ
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1397-1406. PubMed ID: 29314222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma.
    Saviano A; Iezzi R; Giuliante F; Salvatore L; Mele C; Posa A; Ardito F; De Gaetano AM; Pompili M;
    J Vasc Interv Radiol; 2017 Nov; 28(11):1512-1519. PubMed ID: 28734848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
    Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
    Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Aby E; Phan J; Truong E; Grotts J; Saab S
    J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
    Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
    J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study.
    Biederman DM; Titano JJ; Bishay VL; Durrani RJ; Dayan E; Tabori N; Patel RS; Nowakowski FS; Fischman AM; Kim E
    Radiology; 2017 Jun; 283(3):895-905. PubMed ID: 27930089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etiopathogenetic Factors of Hepatocellular Carcinoma, Overall Survival, and Their Evolution over Time-Czech Tertiary Center Overview.
    Hříbek P; Klasová J; Tůma T; Kupsa T; Urbánek P
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate Lobe.
    Lee BC; Liu KL; Wu CH; Huang KW; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH; Liang PC
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1699-1707. PubMed ID: 29946941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
    Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
    Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller.
    Kim JW; Kim JH; Sung KB; Ko HK; Shin JH; Kim PN; Choi HK; Ko GY; Yoon HK; Chun SY; Gwon DI
    Am J Gastroenterol; 2014 Aug; 109(8):1234-40. PubMed ID: 24935276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center.
    Bharadwaz A; Bak-Fredslund KP; Villadsen GE; Nielsen JE; Simonsen K; Sandahl TD; Grønbæk H; Nielsen DT
    Acta Radiol; 2016 Jul; 57(7):844-51. PubMed ID: 26342009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.
    Lewandowski RJ; Mulcahy MF; Kulik LM; Riaz A; Ryu RK; Baker TB; Ibrahim SM; Abecassis MI; Miller FH; Sato KT; Senthilnathan S; Resnick SA; Wang E; Gupta R; Chen R; Newman SB; Chrisman HB; Nemcek AA; Vogelzang RL; Omary RA; Benson AB; Salem R
    Radiology; 2010 Jun; 255(3):955-65. PubMed ID: 20501733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.